Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00493480
Status:
COMPLETED
Last Update Posted:
2009-08-10
First Post:
2007-06-27
Brief Title:
Danish Carvedilol Study in Portal Hypertension
Sponsor:
Hvidovre University Hospital
Organization:
Hvidovre University Hospital
Study Overview
Official Title:
Danish Carvedilol Study in Portal Hypertension Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DACAPO
Brief Summary:
Patients with large esophageal varices who have not yet experienced bleeding are normally treated with propranolol a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding 20-40 of the patients do not respond to this treatment or have to discontinue the treatment because of side effects The aim of this study is to evaluate if carvedilol a combined alfa -beta blocker has better efficacy and safety than propranolol in lowering the portal pressure in patients with cirrhosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None